Sai Ganga Panakeia Launches VPK42 Device Docture-Poly, Merging Ayurveda with AI for Precision Care

Breakthrough in Personalized Medicine

The Docture-Poly device captures an individual’s unique metabolic profile using Vata-Pitta-Kapha (VPK) modelling, an innovation derived from three decades of clinical and research work by Dr. Polisetty. This personalized metabolic fingerprint (VPK42) enables Ayurvedic, Naturopathic, and Allopathic practitioners to craft highly tailored interventions.

For example:

• In Pitta-aggravated diabetes, Metformin may be effective.
• In Vata-aggravated cases, herbal eucalyptus may be better suited.

This approach revolutionizes chronic care and bridges the gap between Eastern traditional systems and Western clinical precision — all while adhering to natural, body-compatible methods.

The Scientific Foundation

Unlike commercial wearables, Docture-Poly is born out of bench-to-bedside translational research, incorporating:

• Real-world validation of Ayurvedic concepts in animal models
• Sensor calibration challenges resolved for VPK correlation
• AWS-integrated secure patient data transfer using advanced encryption protocols

Dr. Polisetty — an allopathic paediatric cardiac surgeon, Python programmer, data scientist, naturopath, and current BAMS scholar — brings an unmatched multidimensional insight into health systems. His leadership lends exceptional credibility to the product and the broader Poly Scientific framework the company promotes.

Global Recognition and National Aspiration

Sai Ganga Panakeia’s innovations have been:

• Presented five times to the United Kingdom Parliament
• Presented to the European Parliament
• Recently accredited by the European Commission, further validating the device’s scientific merit and scalability.

The company is now poised to:

• Launch over 2,000 polyclinics across India
• Deploy 8,000+ trained Poly Scientific Doctors
•  Establish 34 hub hospitals (800-bedded) to cover India’s urban health grid
• Provide care to over 3.2 crore end-stage disease patients, improving survival and quality of life

A $1.2 Trillion Global Opportunity

With its FCA-accredited valuation of £1.4 billion, Sai Ganga Panakeia is uniquely positioned to lead the ₹5 lakh crore Indian end-stage care market and influence the $1.2 trillion global personalized and preventive care industry.

As Dr. Polisetty states, “We’re not just building a product; we’re building a new healthcare paradigm — one where India leads the world by at least 15 years, not just in innovation, but in compassion and care.”

Get Involved:

• The device is available at a limited-time pre-booking price of ₹34,000
• Each device supports up to four users — making it ideal for families
• Users get their own digital metabolic doctor, enabling individualized guidance for diet, lifestyle, and prevention

Reach out to us:

Sai Ganga Panakeia which is an unlisted public limited Company with an authorised capital of 10 Cr and with a paid up of 7.5 Cr, with an exceptional body of advisory board members (which involves billionaire business man, Worldclass researchers and clinicians) invites collaborators, investors, researchers, and policy influencers to join hands in building a globally scalable, inclusive, and life-saving healthcare movement.

For media inquiries or partnership opportunities:

Email: info@sgprs.com

Phone: +91-7331109988

Website: www.saigangapanakeia.in

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.